Zealand Pharma A/S
CSE:ZEAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zealand Pharma A/S
CSE:ZEAL
|
DK |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
US |
|
Ginkgo Bioworks Holdings Inc
NYSE:DNA
|
US |
|
Kingdom Holding Company SJSC
SAU:4280
|
SA |
|
AMETEK Inc
NYSE:AME
|
US |
|
R
|
Ratchthani Leasing PCL
SET:THANI
|
TH |
|
I
|
Immuneering Corp
NASDAQ:IMRX
|
US |
|
Hengli Petrochemical Co Ltd
SSE:600346
|
CN |
|
Copart Inc
NASDAQ:CPRT
|
US |
|
ADT Inc
NYSE:ADT
|
US |
|
Standard Motor Products Inc
NYSE:SMP
|
US |
|
Hiab Oyj
F:C1C1
|
FI |
Wall St Price Targets
ZEAL Price Targets Summary
Zealand Pharma A/S
According to Wall Street analysts, the average 1-year price target for
ZEAL is 556.31 DKK with a low forecast of 303 DKK and a high forecast of 950.25 DKK.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ZEAL's stock price target?
Price Target
556.31
DKK
According to Wall Street analysts, the average 1-year price target for
ZEAL is 556.31 DKK with a low forecast of 303 DKK and a high forecast of 950.25 DKK.